Your browser doesn't support javascript.
loading
Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey.
Jackson, James Ds; Cotton, Sarah E; Bruce Wirta, Sara; Proenca, Catia C; Zhang, Milun; Lahoz, Raquel; Balas, Bogdan; Calado, Frederico J.
Afiliação
  • Jackson JD; Real World Research, Adelphi Real World, Bollington, UK, james.jackson@adelphigroup.com.
  • Cotton SE; Real World Research, Adelphi Real World, Bollington, UK, james.jackson@adelphigroup.com.
  • Bruce Wirta S; Real World Evidence, Cardio-Metabolic Franchise, Novartis Sweden AB, Stockholm, Sweden.
  • Proenca CC; Wellmera AG, Basel, Switzerland.
  • Zhang M; Health Economics and Outcomes Research, Novartis Pharma China, Beijing, China.
  • Lahoz R; Medical Affairs, Cardio-Metabolic Franchise, Novartis Pharma AG, Basel, Switzerland.
  • Balas B; Medical Affairs, Cardio-Metabolic Franchise, Novartis Pharma AG, Basel, Switzerland.
  • Calado FJ; Medical Affairs, Cardio-Metabolic Franchise, Novartis Pharma AG, Basel, Switzerland.
Drug Des Devel Ther ; 12: 2311-2321, 2018.
Article em En | MEDLINE | ID: mdl-30100706
ABSTRACT

PURPOSE:

The objective of this study was to describe the clinical care pathways, management and treatment patterns, and hospitalizations for patients with heart failure (HF) in China. SUBJECTS AND

METHODS:

A cross-sectional survey of cardiologists and their patients with HF was conducted. Patient record forms were completed by 150 cardiologists for 10 consecutive patients. Patients for whom a patient record form was completed were invited to complete a patient self-completion questionnaire.

RESULTS:

Most of the 1,500 patients (mean [SD] age 66 [10] years; 55% male) included in the study received care in tier-2 and -3 hospitals in large cities. Cardiologists were responsible for initial consultation, diagnosis, and treatment of patients with HF. The use of guideline-recommended diagnostics was high. However, guideline-recommended double- and triple-combination therapy was received by only 51% and 18% of patients, respectively. In total, 20% of patients with HF reported that they were not consulted on the choice of therapy. Concordance was high (≥80%) between matched cardiologist and patient pairs for the occurrence of side effects, while cardiologists more often under- than overreported the occurrence of side effects of treatment reported by patients.

CONCLUSION:

The management of HF was predominantly overseen by cardiologists. The use of diagnostic tests was high, but the use of guideline-recommended treatment was low in this population. Improved communication between patients and cardiologists is essential to optimize treatment decision making and to increase awareness of treatment side effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article